Literature DB >> 21153087

Collection of blood in heparinized tubes does not alter the molecular distribution or forms of IGFBP-3 and IGF.

S Mandel1, E Moreland, R G Rosenfeld, S E Gargosky.   

Abstract

The major serum carrier of the insulin-like growth factors (IGFs) is IGF-binding protein-3 (IGFBP-3) that exists in the circulation associated with IGF and an acid labile subunit to form a ternary (158-kDa) complex. It has been reported that heparin disrupts the IGF carrying capacity of the ternary complex and is a potent inhibitor of ternary complex reformation (Clemmons et al., 1983; Baxter, 1990). Thus, the aim of this study was to determine if, in a clinical setting where blood may be collected in both nonheparinized and heparinized tubes, heparin alters the molecular distribution or immunoreactive measurement of IGFBP-3 and IGF-I. Two different collection modalities were examined: protocol 1, blood was drawn and immediately centrifuged and aliquotted; and protocol 2, blood was drawn, left at room temperature for 2 h and then at 4°C overnight prior to centrifugation. Samples were drawn from a normal adult and from a growth hormone-deficient (GHD) child and subjected to neutral size-exclusion chromatography to separate the ternary 158-kDa complex from the binary IGFBP-3-IGF (approx 50 kDa) complex. Fractions were then subjected to Western ligand blot (WLB), western immunoblot (WIB), and measurement of IGFBP-3 by immunoradiometric assay (IRMA), while the IGF distribution was measured by radioimmunoassay (RIA) following acidic size-exclusion chromatography. In both serum and plasma of a normal adult, WLB detected a 45-40-kDa IGFBP-3 doublet eluting primarily within the 158-kDa IGFBP region (i.e., ternary complex). Similarly, assessment of immunoreactive IGFBP-3 by WIB showed a 45-40-kDa IGFBP-3 doublet, as well as a 29 kDa immunoreactive form primarily eluting in the 158-kDa IGFBP region of the chromatography. Measurement of IGFBP-3 by IRMA confirmed these findings. No difference between serum and plasma was detected in either collection protocol. RIA of IGF-I revealed that the ternary complex carried the majority of the circulating IGF-I and that there was no difference between serum and plasma. Assessment of serum and plasma of a GHD child showed reduced serum concentrations of IGFBP-3 but no difference in the IGFBP profiles between serum and plasma. These data demonstrate that the collection of blood in heparinized tubes does not alter the molecular distribution or forms of IGFBP-3 and IGF-I.

Entities:  

Year:  1996        PMID: 21153087     DOI: 10.1007/BF02738649

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  29 in total

Review 1.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.

Authors:  W H Daughaday; P Rotwein
Journal:  Endocr Rev       Date:  1989-02       Impact factor: 19.871

2.  On the nomenclature of the IGF binding proteins.

Authors:  J Ballard; R Baxter; M Binoux; D Clemmons; S Drop; K Hall; R Hintz; M Rechler; E Rutanen; J Schwander
Journal:  Acta Endocrinol (Copenh)       Date:  1989-11

Review 3.  Binding proteins for the insulin-like growth factors: structure, regulation and function.

Authors:  R C Baxter; J L Martin
Journal:  Prog Growth Factor Res       Date:  1989

Review 4.  Insulin-like growth factors; autocrine, paracrine or endocrine? New perspectives of the somatomedin hypothesis in the light of recent developments.

Authors:  J M Holly; J A Wass
Journal:  J Endocrinol       Date:  1989-09       Impact factor: 4.286

5.  Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling.

Authors:  R C Baxter; J L Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin.

Authors:  D R Clemmons; L E Underwood; P G Chatelain; J J Van Wyk
Journal:  J Clin Endocrinol Metab       Date:  1983-02       Impact factor: 5.958

8.  Glycosaminoglycans inhibit formation of the 140 kDa insulin-like growth factor-binding protein complex.

Authors:  R C Baxter
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

9.  Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome.

Authors:  P Bang; M Degerblad; M Thorén; J Schwander; W Blum; K Hall
Journal:  Acta Endocrinol (Copenh)       Date:  1993-05

10.  The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3.

Authors:  S E Gargosky; K F Wilson; P J Fielder; M A Vaccarello; J Guevara-Aguirre; F B Diamond; R C Baxter; A L Rosenbloom; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

View more
  1 in total

1.  The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunit, and growth rate in GH-deficient children.

Authors:  S H Mandel; E Moreland; R G Rosenfeld; S E Gargosky
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.